Senseonics (NYSEAMERICAN:SENS) issued its earnings results on Thursday. The company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.05), Fidelity Earnings reports. The business had revenue of $3.42 million for the quarter, compared to analyst estimates of $4.05 million.
Shares of SENS traded down $0.22 during mid-day trading on Friday, hitting $2.14. The company’s stock had a trading volume of 1,631,581 shares, compared to its average volume of 1,702,662. Senseonics has a 52-week low of $1.93 and a 52-week high of $5.29.
A number of brokerages have commented on SENS. Piper Jaffray Companies began coverage on shares of Senseonics in a research note on Tuesday, January 29th. They issued a “neutral” rating on the stock. Zacks Investment Research downgraded shares of Senseonics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 30th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $6.00.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Raymond James Trust N.A. lifted its position in shares of Senseonics by 11.4% in the 4th quarter. Raymond James Trust N.A. now owns 49,000 shares of the company’s stock worth $127,000 after purchasing an additional 5,000 shares during the period. Cerity Partners LLC lifted its position in shares of Senseonics by 33.3% in the 4th quarter. Cerity Partners LLC now owns 20,000 shares of the company’s stock worth $52,000 after purchasing an additional 5,000 shares during the period. Cetera Advisors LLC lifted its position in shares of Senseonics by 10.8% in the 1st quarter. Cetera Advisors LLC now owns 56,500 shares of the company’s stock worth $133,000 after purchasing an additional 5,500 shares during the period. Amalgamated Bank purchased a new stake in shares of Senseonics in the 4th quarter worth approximately $28,000. Finally, Principal Financial Group Inc. lifted its position in shares of Senseonics by 78.0% in the 4th quarter. Principal Financial Group Inc. now owns 25,259 shares of the company’s stock worth $65,000 after purchasing an additional 11,071 shares during the period. 30.66% of the stock is owned by hedge funds and other institutional investors.
WARNING: This article was originally reported by Tech Know Bits and is the property of of Tech Know Bits. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://techknowbits.com/2019/05/11/senseonics-sens-issues-earnings-results.html.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Featured Story: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Senseonics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Senseonics and related companies with MarketBeat.com’s FREE daily email newsletter.